PDF factsheet
      Z

cholesterol lowering intervention in cardiovascular prevention for patients with renal insufficiency (on hemodialysis or transplant), clinical trials results

atorvastatin versus placebo
Deutsche Diabetes Dialyse Studie (4D), 2005
atorvastatin 20mg daily
versus
matching placebo
patients with type 2 diabetes mellitus on maintenance hemodialysisdouble blind
Follow-up duration: 4 y (median)
ezetimibe+simvastatin versus placebo
SHARP, 2010
NCT00125593
Simvastatin 20mg/Ezetimibe 10mg
versus
placebo
patients with established chronic kidney disease (dialysis or pre-dialysis)double-blind
Follow-up duration: 4.9 years
20 countries
fluvastatin versus placebo
ALERT, 2003
fluvastatin
versus
placebo
renal transplant recipients with total cholesterol 4·0–9·0 mmol/L.double blind
Follow-up duration: 5.1 years
rosuvastatin versus placebo
AURORA, 2009
rosuvastatin 10 mg daily
versus
placebo
in patients with end-stage renal disease on hemodialysis double blind
Follow-up duration: 3.2 y mean (max 5.6y)

  Options


in first

in second

  Filter